Docbot Collaborates with Eli Lilly Study, Findings Show Promise for AI Tech in Endoscopic Procedures

Docbot, a startup and graduate of UCI Beall Applied Innovation’s Wayfinder program that uses an artificial intelligence-enabled platform to identify colon polyps in real time, recently published a collaborative study with Eli Lilly and Company. The study, published in leading journal “Gastroenterology,” is the first to demonstrate that a deep learning artificial intelligence (AI) can be trained to automatically predict levels of ulcerative colitis severity using endoscopic videos.

“We’re excited to announce results of our collaboration for developing an AI for ulcerative colitis with Lilly, who we recognize as a visionary leader in the pharmaceutical industry,” said Andrew Ninh, co-founder and CEO of Docbot, in a press release. “We’re pleased to partner and collaborate with their team to spearhead a game-changing effort that may positively impact patients suffering with ulcerative colitis.”

Ulcerative colitis, an inflammatory bowel disease with no known cure, is identified using endoscopic disease activity scoring, or where a small camera is used to view the digestive track. According to Docbot’s press release, the procedure is expensive and requires a medically trained professional.

With Docbot’s technology, according to the recent study, their AI-driven platform can be utilized to identify ulcerative colitis accurately using full-length endoscopic videos, which saves time and money for both the healthcare industry and patients.

Since the study’s successful findings, Docbot and Eli Lilly continue to collaborate to find new ways of automating the process of endoscopic disease activity scoring in ulcerative colitis.

Learn more about Docbot.

Main Graphic: Kate Wokowsky, UCI Beall Applied Innovation

Read the original story.